📊 IVVD Key Takeaways
Is IVVD a Good Investment? Thesis Analysis
Invivyd is a pre-commercial or early-stage biopharmaceutical company with severe profitability challenges, burning $58.1M in operating cash flow annually despite 110.5% revenue growth. While the company maintains strong liquidity with $226.7M in cash and minimal debt, the current burn rate combined with negative 98.2% net margins and -109.1% free cash flow margin indicates the business model is not yet viable at scale.
Why Buy IVVD? Key Strengths
- Strong revenue growth of 110.5% YoY indicates market traction and demand
- Excellent liquidity position with $226.7M cash and 7.24x current ratio provides runway for operations
- Negligible debt burden (0.00x debt-to-equity) provides financial flexibility without leverage risk
IVVD Investment Risks to Consider
- Massive cash burn of $58.1M annually in operating activities threatens sustainability despite large cash reserves
- Severely negative profitability metrics (net margin -98.2%, operating margin -104%) indicate business is unprofitable at scale
- At current burn rate, cash runway appears limited to approximately 3.9 years, requiring path to profitability within that window
- 10 Form 4 insider filings in 90 days may signal insider concerns or management transitions
Key Metrics to Watch
- Operating cash burn rate - critical to track if burn is decelerating with growing revenue
- Gross margin achievement - need visibility on gross profitability to assess unit economics
- Revenue growth sustainability - monitor if 110% growth can be maintained and convert to profitability
- Cash burn runway and path to breakeven - essential for assessing going concern risks
IVVD Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.24x current ratio provides a solid financial cushion.
IVVD Profitability Ratios
IVVD vs Healthcare Sector
How Invivyd, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is IVVD Overvalued or Undervalued?
Based on fundamental analysis, Invivyd, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
IVVD Balance Sheet & Liquidity
IVVD 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Invivyd, Inc.'s revenue has grown significantly by 110% over the 5-year period, indicating strong business expansion. The most recent EPS of $-1.43 indicates the company is currently unprofitable.
IVVD Growth Metrics (YoY)
IVVD Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $9.3M | -$10.5M | $-0.06 |
| Q2 2025 | $2.3M | -$14.7M | $-0.12 |
| Q1 2025 | N/A | -$16.3M | $-0.14 |
| Q3 2024 | N/A | -$35.3M | $-0.36 |
| Q2 2024 | N/A | -$35.3M | $-0.40 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
IVVD Capital Allocation
IVVD SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Invivyd, Inc. (CIK: 0001832038)
📋 Recent SEC Filings
❓ Frequently Asked Questions about IVVD
What is the AI rating for IVVD?
Invivyd, Inc. (IVVD) has an AI rating of SELL with 85% confidence, based on fundamental analysis of SEC EDGAR filings.
What are IVVD's key strengths?
Claude: Strong revenue growth of 110.5% YoY indicates market traction and demand. Excellent liquidity position with $226.7M cash and 7.24x current ratio provides runway for operations.
What are the risks of investing in IVVD?
Claude: Massive cash burn of $58.1M annually in operating activities threatens sustainability despite large cash reserves. Severely negative profitability metrics (net margin -98.2%, operating margin -104%) indicate business is unprofitable at scale.
What is IVVD's revenue and growth?
Invivyd, Inc. reported revenue of $53.4M.
Does IVVD pay dividends?
Invivyd, Inc. does not currently pay dividends.
Where can I find IVVD SEC filings?
Official SEC filings for Invivyd, Inc. (CIK: 0001832038) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is IVVD's EPS?
Invivyd, Inc. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is IVVD a good stock to buy right now?
Based on our AI fundamental analysis in March 2026, Invivyd, Inc. has a SELL rating with 85% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is IVVD stock overvalued or undervalued?
Valuation metrics for IVVD: ROE of -21.7% (sector avg: 15%), net margin of -98.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy IVVD stock in 2026?
Our dual AI analysis gives Invivyd, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is IVVD's free cash flow?
Invivyd, Inc.'s operating cash flow is $-58.1M, with capital expenditures of $155.0K. FCF margin is -109.1%.
How does IVVD compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -98.2% (avg: 12%), ROE -21.7% (avg: 15%), current ratio 7.24 (avg: 2).